Discovery could lead to higher immunotherapy response rates for bladder cancer patients

August 29, 2018, The Mount Sinai Hospital
Credit: CC0 Public Domain

Mount Sinai researchers have discovered that a particular type of cell present in bladder cancer may be the reason why so many patients do not respond to the groundbreaking class of drugs known as PD-1 and PD-L1 immune checkpoint inhibitors, which enable the immune system to attack tumors.

In a study published in August in Nature Communications, the Mount Sinai team reported that , a subset of often found in the tumor environment, may be preventing known as T- from seeking out and destroying the invading . The researchers showed that expression of a set of genes that are typically linked to more aggressive cancers was actually more commonly linked to stromal cells rather than cells themselves. They also showed that tumors with increased expression of these genes, known as epithelial mesenchymal transition genes, did not respond well to immune checkpoint inhibitors. The researchers also found that in such tumors, T-cells were more likely to be separated from cancer cells by the stromal cells, suggesting that the stromal cells may be hindering the ability of the immune cells to reach and eradicate the cancer cells.

"Some bladder cancers may not respond to immunotherapy, even though the body has developed an immune response against them, because the T-cells are prevented from reaching the tumor by stromal cells that create an inhospitable 'neighborhood,'" said Matthew Galsky, MD, Professor of Medicine and Director of Genitourinary Medical Oncology at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai, and senior author of the study.

Dr. Galsky and his colleagues are now trying to validate the gene expression identified in their study as a biomarker that could help refine clinical trials and treatment in the future by predicting the level of response or resistance to PD-1/PD-L1 inhibitors. In addition, according to Dr. Galsky, the group is identifying ways to "counteract the negative impact of the stromal cells and make that neighborhood more friendly to immune cells so they can finish their job."

Since they were made available to patients about four years ago, immune checkpoint inhibitors have changed the treatment landscape for many types of cancer, particularly , which had gone several decades without significant therapeutic advances. While five different PD-1 and PD-L1 inhibitors have since been approved by the U.S. Food and Drug Administration, responses are achieved in only 15 percent to 25 percent of patients. Cancer researchers have turned their attention to attempting to learn why and, more specifically, to discovering ways to increase the proportion of patients with positive results.

The Mount Sinai team used several data sets for their study, including genomic data from The Cancer Genome Atlas' bladder cancer dataset from the National Cancer Institute. In addition, in collaboration with researchers from Bristol-Myers Squibb, they demonstrated the potential clinical relevance of their findings in a large clinical trial dataset derived from patients with metastatic bladder cancer treated with the PD-1 inhibitor nivolumab.

"Our biologists and biostatisticians were able to harness 'big data' to generate valuable insights into responses and resistance to PD-1 therapies," noted study co-author Jun Zhu, Ph.D., Professor in the Department of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai and Head of Data Sciences at Sema4, a Mount Sinai venture. "We strongly believe those results will inform future studies at Mount Sinai and elsewhere."

Dr. Galsky added, "What our group has done is add another important piece to a larger jigsaw puzzle about why PD-1/PD-L1 inhibitors don't work in some patients. Through our work we have supported and extended important observations made by other researchers, and this makes us more confident than ever that we are on the right track to addressing a huge unmet need for patients with bladder cancer."

Explore further: Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer

Related Stories

Simultaneous chemo and immunotherapy may be better for some with metastatic bladder cancer

April 11, 2018
Researchers from Mount Sinai and Sema4, a health information company and Mount Sinai venture, have discovered that giving metastatic bladder cancer patients simultaneous chemotherapy and immunotherapy is safe and that patients ...

Discovery of new biomarker could provide personalized treatment options for bladder cancer

July 2, 2018
A potential new target for treatment has been identified in an aggressive form of bladder cancer, Mount Sinai researchers report in a recent study. Bladder cancers are categorized into subtypes based on molecular features. ...

Researchers artificially generate immune cells integral to creating cancer vaccines

August 14, 2018
For the first time, Mount Sinai researchers have identified a way to make large numbers of immune cells that can help prevent cancer reoccurrence, according to a study published in August in Cell Reports.

Bladder cancer model could pave the way for better drug efficacy studies

May 21, 2018
Understanding that not all bladder cancers are the same, researchers at the University of North Carolina Lineberger Comprehensive Cancer Center have created a tool that may help them to uncover why only a fraction of patients ...

Genetic material once considered junk actually could hold key to cancer drug response

April 3, 2018
Material left out of common processes for sequencing genetic material in cancer tumors may actually carry important information about why only some people respond to immunotherapy, possibly offering better insight than the ...

Researchers find potential key to unlocking the immune system in pancreatic cancer

August 6, 2018
A University of North Carolina Lineberger Comprehensive Cancer Center study may provide insights into how to overcome barriers to using immune-based treatments for pancreatic cancer, the third most deadly cancer in the United ...

Recommended for you

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

New way to target advanced breast cancers

September 20, 2018
A cytokine signature found in certain kinds of breast cancer cells can not only serve as a diagnostic tool for HER2-negative cancers but also offer an effective treatment target.

Understanding epilepsy in pediatric tumors

September 20, 2018
Pediatric brain tumors are characterized by frequent complications due to intractable epilepsy compared to adult brain tumors. However, the genetic cause of refractory epilepsy in pediatric brain cancer has not been elucidated ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.